Chronic Heart Failure (CHF) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Chronic Heart Failure (CHF) Market Outlook

Thelansis’s “Chronic Heart Failure (CHF) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Chronic Heart Failure treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Chronic Heart Failure (CHF) Overview

Chronic heart failure (CHF) is a multifaceted syndrome stemming from structural and functional disturbances, impairing the heart's oxygen supply to tissues and significantly impacting quality of life, socio-economic status, and healthcare costs globally. Its primary cause is coronary artery disease. Identifying patients at risk of progression and sudden death often involves assessing etiological phenotype, ejection fraction decline, and QRS duration widening on ECG, potentially leading to prophylactic implantable cardioverter-defibrillator placement with or without cardiac resynchronization therapy. Various conditions can mimic CHF symptoms, including diastolic heart failure (preserved ejection fraction), chronic thromboembolic disease, chronic angina, pulmonary hypertension, and chronic lung ailments such as interstitial lung disease and COPD. CHF treatment encompasses various approaches, including general measures, stage-specific pharmacotherapy, device interventions, and heart transplantation. Initiation of pharmacological therapy with ACE inhibitors or ARBs is recommended in NYHA stage I, followed by beta-blockers in stage II and aldosterone antagonists in stage III, contributing to reduced mortality rates. Symptomatic relief is achieved through the use of diuretics, digitalis, anti-arrhythmics, and inotropics. Survival rates can be improved for selected patients through interventions such as implantable cardioverter-defibrillator (ICD) placement, cardiac resynchronization therapy (CRT), ventricular assist devices (VADs), and, ultimately, heart transplantation. In the United States, over 5 million people live with CHF, with approximately 600,000 new diagnoses annually.

• The prevalence of CHF increases with advancing life span, with diastolic heart failure predominating in the elderly population.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: